1. A pharmacology student is asked to compare the ribosomal mechanisms of chloramphenicol and linezolid. Both drugs target the 50S ribosomal subunit, yet they are described as acting at fundamentally different steps in bacterial protein synthesis. Which of the following best distinguishes the mechanistic step at which each drug acts?
A) Chloramphenicol blocks the formation of the 70S initiation complex before translation begins, while linezolid acts at the peptidyl transferase center during elongation to prevent peptide bond formation between the growing chain and the incoming aminoacyl-tRNA
B) Both chloramphenicol and linezolid act at identical binding sites on the 23S rRNA of the 50S subunit; the distinction between them is pharmacokinetic rather than mechanistic, with linezolid achieving higher intracellular concentrations that produce a functionally different outcome
C) Chloramphenicol binds the 23S rRNA at the peptidyl transferase center and blocks peptide bond formation during the elongation phase of translation, after the 70S initiation complex has already assembled; linezolid binds the 50S subunit at a site that prevents assembly of the 30S initiation complex with the 50S subunit, blocking translation before elongation can begin
D) Chloramphenicol inhibits ribosome recycling after termination, preventing the 70S complex from dissociating into 30S and 50S subunits for re-use; linezolid blocks the initial 70S assembly step, meaning the two drugs together produce additive inhibition of the complete ribosome cycle
E) Both drugs act exclusively at the elongation phase; the distinction is that chloramphenicol blocks translocation of the peptidyl-tRNA from the A site to the P site, while linezolid prevents accommodation of the incoming aminoacyl-tRNA into the empty A site
ANSWER: C
Rationale:
Chloramphenicol and linezolid both bind to the 23S rRNA of the 50S ribosomal subunit, but they act at entirely different functional steps in protein synthesis. Chloramphenicol occupies the peptidyl transferase center — the catalytic site that forms the peptide bond between the growing polypeptide chain and the incoming aminoacyl-tRNA during the elongation phase. It acts after the 70S initiation complex has fully assembled and translation is underway. Linezolid, by contrast, binds a site on the 50S subunit that overlaps the A site and peptidyl transferase center but exerts its primary effect earlier — it prevents the 30S initiation complex (carrying mRNA and initiator fMet-tRNA) from assembling with the 50S subunit to form a functional 70S initiation complex, blocking translation before elongation can begin. This pre-initiation mechanism is unique among all clinically used ribosomal inhibitors. Because their binding sites on the 50S subunit are distinct, resistance mechanisms conferring chloramphenicol resistance do not automatically confer linezolid resistance, and vice versa.
Option A: Option A is incorrect because it reverses the mechanisms of the two drugs: it assigns the pre-initiation block to chloramphenicol and the elongation block to linezolid, which is the opposite of the established pharmacology.
Option B: Option B is incorrect because the distinction between chloramphenicol and linezolid is mechanistic — they act at different steps in translation — not merely pharmacokinetic; their binding sites on the 50S subunit overlap but are functionally distinct, and intracellular concentration differences do not explain the difference in translational step targeted.
Option D: Option D is incorrect because chloramphenicol does not inhibit ribosome recycling after termination; it acts during elongation at the peptidyl transferase step, and no clinically used antibiotic class acts by preventing post-termination ribosome dissociation as its primary mechanism.
Option E: Option E is incorrect because neither drug acts primarily on translocation (the step involving movement of peptidyl-tRNA from A to P site); that step is blocked by fusidic acid; and linezolid's mechanism is not accommodation of aminoacyl-tRNA into the A site during elongation but rather pre-initiation complex formation, which occurs before the elongation cycle begins.
2. A 10-day-old premature neonate receives chloramphenicol at a dose calculated for a 6-month-old infant. Over the following 48 hours the nursing staff document abdominal distension, vomiting, refusal to feed, progressive cyanosis, and an ashen gray skin discoloration. Cardiovascular monitoring shows hypotension and bradycardia. Which of the following best explains the mechanism producing this clinical picture?
A) Neonatal hepatic glucuronidation is immature, preventing normal conjugation and clearance of chloramphenicol; the drug accumulates to toxic concentrations and inhibits mitochondrial protein synthesis in cardiac and skeletal muscle, producing dose-dependent myocardial depression and cardiovascular collapse — the syndrome known as gray baby syndrome
B) The neonate's immature renal tubular secretion allows chloramphenicol to accumulate in the bloodstream; the resulting high plasma levels activate cardiac muscarinic receptors, producing bradycardia and vasodilation through a direct autonomic mechanism unrelated to mitochondrial toxicity
C) Chloramphenicol competitively displaces bilirubin from neonatal plasma albumin, causing bilirubin to cross the blood-brain barrier; the resulting kernicterus produces the described neurological and cardiovascular findings through CNS toxicity rather than direct myocardial depression
D) The dose used exceeded the maximum plasma concentration threshold of 10 mcg/mL at which chloramphenicol becomes cardiotoxic in all patients regardless of age; the gray skin color reflects tissue hypoxia from peripheral vasoconstriction caused by direct alpha-adrenergic stimulation
E) Immature neonatal CYP3A4 (cytochrome P450 3A4) fails to hydroxylate chloramphenicol to its active metabolite; the unmetabolized parent compound accumulates and binds irreversibly to cardiac mitochondria, producing permanent rather than reversible myocardial dysfunction
ANSWER: A
Rationale:
Gray baby syndrome results from chloramphenicol accumulation caused by immature hepatic glucuronidation in neonates, particularly premature infants. Glucuronosyltransferase enzymes that conjugate chloramphenicol to an inactive, water-soluble glucuronide for renal excretion are not yet functionally developed in the neonatal liver. When a dose appropriate for older children is administered to a neonate, chloramphenicol is not adequately cleared, and plasma concentrations rise to toxic levels. The accumulated drug inhibits mitochondrial protein synthesis in cardiac and skeletal muscle — the same biochemical mechanism responsible for its antibacterial effect — producing direct myocardial depression. The clinical syndrome includes abdominal distension, vomiting, refusal to feed, progressive cyanosis, ashen gray skin color (from poor peripheral perfusion), hypotension, and cardiovascular collapse. The condition is potentially fatal without supportive care and drug discontinuation. When chloramphenicol must be used in neonates, it must be given at substantially reduced doses (25 mg/kg/day) with serum level monitoring.
Option B: Option B is incorrect because chloramphenicol is not primarily cleared by renal tubular secretion; it is metabolized by hepatic glucuronidation, and the clinical syndrome is caused by direct mitochondrial toxicity, not by muscarinic receptor activation or autonomic dysfunction.
Option C: Option C is incorrect because bilirubin displacement from albumin is a recognized concern with certain drugs in neonates (sulfonamides are the classic example), but it is not the mechanism of gray baby syndrome; chloramphenicol toxicity produces mitochondrial myocardial depression, not kernicterus, and the gray skin color reflects cardiovascular collapse rather than bilirubin-related neurological damage.
Option D: Option D is incorrect because the toxicity threshold for gray baby syndrome is not a fixed plasma concentration that applies equally to all patients; it occurs specifically in neonates because of impaired metabolic clearance, not because a universal cardiotoxic threshold was exceeded; and the mechanism does not involve alpha-adrenergic stimulation.
Option E: Option E is incorrect because chloramphenicol is primarily metabolized by glucuronidation, not by CYP3A4 hydroxylation; it does not require CYP metabolism for inactivation, and its toxicity is a reversible mitochondrial effect, not irreversible binding.
3. A child with bacterial meningitis and severe penicillin allergy is started on intravenous chloramphenicol. The clinical pharmacist recommends serum chloramphenicol level monitoring and notes that the IV formulation has a pharmacokinetic disadvantage compared to oral chloramphenicol. Which of the following best explains this disadvantage and its clinical implication?
A) Intravenous chloramphenicol bypasses first-pass hepatic metabolism entirely, producing higher and less predictable peak plasma concentrations than oral dosing; serum monitoring is required to prevent toxicity from supratherapeutic peaks
B) Intravenous chloramphenicol is directly neurotoxic at peak concentrations above 20 mcg/mL because it crosses the blood-brain barrier before hepatic clearance can occur; serum monitoring prevents CNS accumulation by triggering dose reduction when levels approach this threshold
C) Intravenous chloramphenicol distributes preferentially into the cerebrospinal fluid before reaching systemic equilibrium, producing falsely low plasma levels that underestimate CNS drug exposure; serum monitoring must be supplemented by CSF sampling in meningitis cases
D) Intravenous chloramphenicol is formulated as chloramphenicol succinate, a prodrug that requires hydrolysis by plasma and tissue esterases to release the active base; this hydrolysis is variable and often incomplete, with a portion of the prodrug excreted unchanged in urine before conversion, resulting in lower and less predictable plasma concentrations of active drug than those achieved with oral dosing of the active base compound
E) Intravenous chloramphenicol has a shorter half-life than the oral formulation because parenteral administration activates a feedback mechanism that accelerates glucuronidation; serum monitoring is required to detect autoinduction and adjust dosing intervals accordingly
ANSWER: D
Rationale:
Chloramphenicol for intravenous administration is formulated as chloramphenicol succinate, a water-soluble ester prodrug. After administration, plasma and tissue esterases must hydrolyze the succinate ester to release the pharmacologically active chloramphenicol base. This hydrolysis step is variable among patients and is frequently incomplete — a portion of the succinate ester is excreted unchanged in the urine before hydrolysis occurs, meaning that a clinically significant fraction of the administered dose is lost without generating active drug. The result is that IV chloramphenicol succinate produces lower and less predictable plasma concentrations of active drug than oral chloramphenicol base, which is absorbed directly from the gastrointestinal tract with approximately 75 to 90% bioavailability as the active compound. This pharmacokinetic limitation of the IV formulation is a specific reason why serum level monitoring is especially important when the parenteral route is used — the clinician cannot reliably predict plasma levels from dose alone. In some circumstances where the patient can take oral medications, oral dosing may actually provide more reliable drug exposure.
Option A: Option A is incorrect because intravenous chloramphenicol does not produce higher plasma concentrations than oral dosing; the opposite is the pharmacokinetic concern — the IV prodrug formulation produces lower concentrations due to incomplete hydrolysis; the premise of supratherapeutic peaks from bypassing first-pass metabolism does not apply to a prodrug requiring activation.
Option B: Option B is incorrect because chloramphenicol's CNS penetration (30 to 50% of plasma) is a pharmacokinetic advantage that applies equally to IV and oral routes; direct CNS neurotoxicity at specific plasma peaks is not the basis for monitoring; monitoring targets the therapeutic range of 10 to 20 mcg/mL for efficacy and the toxic threshold above approximately 25 mcg/mL for preventing reversible myelosuppression.
Option C: Option C is incorrect because while chloramphenicol does achieve excellent CSF penetration, it does not preferentially distribute into CSF before reaching systemic equilibrium; plasma levels are the standard monitoring target; and supplemental CSF sampling is not part of routine chloramphenicol monitoring for meningitis.
Option E: Option E is incorrect because the IV formulation does not have a shorter half-life due to feedback autoinduction of glucuronidation; autoinduction of chloramphenicol metabolism with prolonged use has been described but is not a mechanism triggered by parenteral administration specifically, and the half-life difference between IV and oral formulations relates to bioavailability of active drug, not to altered elimination kinetics.
4. An infectious disease attending presents two patients who developed hematologic complications during chloramphenicol therapy. Patient 1: a 45-year-old who after 3 weeks of therapy has a serum chloramphenicol level of 30 mcg/mL, pancytopenia with vacuolated marrow precursors, and full recovery after drug discontinuation. Patient 2: a 38-year-old who presents 6 weeks after completing a 10-day chloramphenicol course with progressive bone marrow failure; serum levels during treatment were within the therapeutic range of 10 to 20 mcg/mL, and bone marrow biopsy shows near-complete aplasia with greater than 50% mortality risk without transplantation. Which of the following correctly identifies the mechanism distinguishing these two presentations?
A) Both patients experienced the same mechanism — idiosyncratic immune destruction of hematopoietic stem cells by nitroso-chloramphenicol metabolites — but Patient 1 recovered because the reaction was detected early; earlier detection through serum level monitoring can prevent progression to irreversible aplasia in all cases
B) Patient 1 has dose-dependent reversible bone marrow suppression caused by mitochondrial protein synthesis inhibition in hematopoietic precursors, predictably related to supratherapeutic plasma levels and fully reversible on drug discontinuation; Patient 2 has idiosyncratic aplastic anemia caused by toxic destruction of hematopoietic stem cells by chloramphenicol metabolites, unrelated to dose or plasma concentration, unpredictable, presenting weeks after drug exposure, and irreversible without transplantation or immunosuppression
C) Patient 1 has an immune-mediated drug reaction in which chloramphenicol-specific IgE antibodies coat bone marrow precursors and activate complement-mediated lysis; this is the more dangerous form; Patient 2 has a milder pharmacological effect from residual drug accumulation in marrow stroma after drug discontinuation
D) Both presentations reflect the same dose-dependent mitochondrial toxicity; the difference is that Patient 2's normal therapeutic levels produced toxicity because of a pharmacogenomic variant in glucuronidation enzymes that increased bioavailability of the nitroso reduction product; genetic screening prior to chloramphenicol use would prevent both forms
E) Patient 1 has reversible aplastic anemia caused by CYP2C19 inhibition that allowed chloramphenicol to accumulate despite apparently normal serum levels; Patient 2 has a separate immune-mediated agranulocytosis triggered by chloramphenicol's nitro group interacting with HLA-DQ surface antigens on marrow stromal cells
ANSWER: B
Rationale:
These two patients illustrate the two mechanistically distinct forms of chloramphenicol bone marrow toxicity that must not be confused. Patient 1 has dose-dependent, reversible bone marrow suppression. The key features are: supratherapeutic serum level (30 mcg/mL, above the approximately 25 mcg/mL toxicity threshold), pancytopenia appearing during active treatment after several weeks, bone marrow showing vacuolated erythroid and myeloid precursors (characteristic of mitochondrial toxicity in dividing cells), and full reversibility on drug discontinuation. The mechanism is inhibition of mitochondrial protein synthesis in marrow precursors — the same mechanism as the antibacterial effect. This toxicity is predictable, monitorable, and reversible. Patient 2 has idiosyncratic aplastic anemia — a completely different entity. The features are: normal therapeutic levels during treatment, onset weeks after the course was completed, near-complete marrow aplasia on biopsy, and greater than 50% mortality without definitive treatment. The mechanism involves toxic destruction of hematopoietic stem cells by chloramphenicol metabolites (particularly nitroso-chloramphenicol), is unrelated to dose or plasma concentration, cannot be predicted by monitoring, and results in irreversible stem cell loss.
Option A: Option A is incorrect because the two patients do not share the same mechanism; Patient 1's reversible suppression and Patient 2's aplastic anemia are mechanistically distinct events; serum level monitoring can prevent the dose-dependent reversible form but has no protective effect against idiosyncratic aplastic anemia, which cannot be anticipated or prevented by any monitoring strategy.
Option C: Option C is incorrect because the descriptions are reversed in severity — reversible bone marrow suppression (Patient 1) is the less dangerous form, while aplastic anemia (Patient 2) carries greater than 50% mortality without transplantation; and IgE-mediated complement lysis is not the mechanism of either form of chloramphenicol marrow toxicity.
Option D: Option D is incorrect because aplastic anemia is idiosyncratic and is not the result of pharmacogenomic variants in glucuronidation producing dose-dependent toxicity at normal levels; characterizing both as the same mechanism misrepresents the fundamental distinction and would mislead clinical decision-making.
Option E: Option E is incorrect because CYP2C19 inhibition is a drug interaction effect of chloramphenicol on other drugs, not a mechanism by which chloramphenicol accumulates in its own toxicity; and HLA-DQ-mediated agranulocytosis is not the established mechanism of chloramphenicol aplastic anemia.
5. A 54-year-old patient with a seizure disorder managed on phenytoin (plasma level stable at 15 mcg/mL for 2 years) requires chloramphenicol for a serious infection. Four days after starting chloramphenicol, he develops nystagmus, ataxia, and confusion. A repeat phenytoin level is 38 mcg/mL. Which of the following best explains this clinical scenario and identifies the correct management?
A) Chloramphenicol induces CYP2C9 and CYP2C19, accelerating phenytoin metabolism and reducing its plasma concentration; the neurological symptoms represent breakthrough seizure activity from subtherapeutic phenytoin; the phenytoin dose must be increased immediately
B) Chloramphenicol displaces phenytoin from plasma protein binding sites, acutely increasing the free phenytoin fraction; total phenytoin levels appear elevated while free levels are paradoxically reduced; free phenytoin monitoring would reveal the true therapeutic deficiency
C) Chloramphenicol reduces renal tubular secretion of phenytoin, causing phenytoin accumulation; the correct management is to increase fluid intake to enhance phenytoin renal clearance and normalize plasma concentrations
D) The elevated phenytoin level reflects phenytoin autoinduction of its own metabolism being suppressed by chloramphenicol competition at the CYP3A4 active site; phenytoin normally induces CYP3A4 to accelerate its own clearance, and chloramphenicol blocks this autoinduction pathway
E) Chloramphenicol is a potent inhibitor of CYP2C19, the primary enzyme responsible for phenytoin metabolism; co-administration reduces phenytoin clearance, causing phenytoin to accumulate to toxic concentrations despite an unchanged dose; the neurological findings represent phenytoin toxicity and the chloramphenicol-phenytoin combination requires urgent reassessment with either substitution of the antibiotic or close phenytoin level monitoring and dose reduction
ANSWER: E
Rationale:
Chloramphenicol is a potent inhibitor of CYP2C19 and also inhibits CYP2C9, the primary cytochrome P450 isoforms responsible for phenytoin metabolism. When chloramphenicol is added to a stable phenytoin regimen, it reduces phenytoin clearance by blocking the hepatic enzymatic pathway that normally inactivates phenytoin. The unchanged phenytoin dose now produces higher and higher plasma concentrations because the drug is not being metabolized at the expected rate. The patient in this scenario has gone from a therapeutic phenytoin level of 15 mcg/mL to a toxic level of 38 mcg/mL within 4 days — a more than doubling — producing the classic phenytoin toxicity syndrome of nystagmus, ataxia (cerebellar signs), and altered mental status. The appropriate management is urgent recognition of the interaction, consideration of whether chloramphenicol can be substituted with a safer antibiotic, or if chloramphenicol must continue, immediate dose reduction of phenytoin and close level monitoring.
Option A: Option A is incorrect because chloramphenicol inhibits CYP enzymes — it does not induce them; enzyme induction would accelerate phenytoin metabolism and reduce plasma levels, which is the opposite of what occurred in this patient; the symptoms represent toxicity from elevated phenytoin, not breakthrough seizures from reduced levels.
Option B: Option B is incorrect because protein displacement by chloramphenicol is not the established mechanism of the phenytoin interaction; protein displacement as an isolated mechanism does not typically produce sustained clinically significant toxicity because free drug rapidly redistributes into tissues; the markedly elevated total phenytoin level of 38 mcg/mL is inconsistent with a displacement effect and is consistent with reduced hepatic clearance.
Option C: Option C is incorrect because phenytoin is not primarily cleared by renal tubular secretion; it is almost entirely hepatically metabolized to inactive hydroxylated metabolites; renal excretion of unchanged phenytoin is negligible, and increasing fluid intake would have no meaningful effect on phenytoin clearance.
Option D: Option D is incorrect because phenytoin autoinduction involves CYP3A4 induction, not CYP3A4 inhibition by chloramphenicol at a shared active site; phenytoin's main metabolic pathway is CYP2C9/2C19 hydroxylation, not CYP3A4; and the elevated phenytoin level is explained by chloramphenicol's inhibition of CYP2C19, not by suppression of autoinduction.
6. A 61-year-old hospitalized patient with MRSA pneumonia has been receiving linezolid 600 mg IV every 12 hours for 6 days and is showing clear clinical improvement. She is now tolerating oral intake and has no gastrointestinal pathology. The hospitalist asks the pharmacist whether transition to oral linezolid is appropriate and what dose to use. Which of the following is the pharmacokinetically correct recommendation?
A) Oral linezolid should be initiated at 400 mg every 12 hours — a 33% dose reduction from the IV regimen — because intestinal absorption introduces variability that requires a safety margin below the intravenous dose to prevent supratherapeutic plasma concentrations
B) Oral linezolid cannot be used for MRSA pneumonia because the drug requires high pulmonary epithelial lining fluid concentrations achievable only through direct systemic delivery via the intravenous route; oral absorption results in drug delivery to the portal circulation first, reducing pulmonary drug concentrations
C) Oral linezolid 600 mg every 12 hours — the identical dose and schedule as the IV formulation — is the correct transition; linezolid has approximately 100% oral bioavailability, making the oral and IV formulations therapeutically equivalent; no dose adjustment is needed, and switching allows removal of IV access with no change in drug exposure or treatment efficacy
D) Oral linezolid requires a loading dose of 1200 mg for the first oral dose to compensate for the absorption lag time that results from gastrointestinal transit before systemic distribution, after which the standard 600 mg every 12 hours schedule resumes
E) Transition to oral linezolid is appropriate, but the dose must be reduced to 300 mg every 8 hours rather than 600 mg every 12 hours because oral linezolid has a shorter effective half-life than the IV formulation due to hepatic first-pass metabolism that degrades approximately 20% of absorbed drug before systemic circulation
ANSWER: C
Rationale:
Linezolid has an oral bioavailability of approximately 100%, making it one of the rare antibiotics where oral and intravenous dosing are completely interchangeable at the same dose. A patient who has been receiving IV linezolid 600 mg every 12 hours and can now tolerate oral intake should be transitioned to oral linezolid 600 mg every 12 hours with no dose adjustment — the systemic drug exposure is identical. This property has important clinical and economic implications: removing IV access reduces catheter-associated infection risk, decreases nursing time, and in many patients facilitates earlier hospital discharge while maintaining therapeutic drug levels. Linezolid is absorbed from the gastrointestinal tract as the active compound (not as a prodrug), and first-pass metabolism is negligible. This stands in sharp contrast to vancomycin, which has essentially zero oral bioavailability for systemic infections and must be continued intravenously.
Option A: Option A is incorrect because oral linezolid does not require dose reduction relative to IV; its approximately 100% oral bioavailability means that the oral and IV formulations produce essentially identical plasma concentration-time profiles; a 33% dose reduction would result in subtherapeutic drug exposure.
Option B: Option B is incorrect because oral linezolid achieves systemic plasma and pulmonary tissue concentrations equivalent to IV; the route of systemic delivery does not preferentially alter pulmonary penetration; linezolid's lung epithelial lining fluid concentrations reflect systemic pharmacokinetics regardless of whether the drug entered via oral or IV administration.
Option D: Option D is incorrect because no loading dose is required for oral-to-IV transition with linezolid; the drug achieves steady-state plasma levels from the ongoing dosing schedule, and there is no absorption lag that would require an initial higher dose to compensate.
Option E: Option E is incorrect because linezolid does not undergo meaningful hepatic first-pass metabolism; it is not metabolized by CYP enzymes and absorption is essentially complete; the oral half-life is the same as the IV half-life (approximately 4.5 to 5.5 hours), and every-8-hour dosing at 300 mg would alter both the dose and frequency without pharmacokinetic justification.
7. A 72-year-old patient in the surgical ICU develops a wound infection with purulent drainage following abdominal surgery. Gram stain of the wound shows Gram-positive cocci in clusters and Gram-negative rods. Culture results are pending. The surgical team considers starting linezolid monotherapy. Which of the following is the most important pharmacological reason this plan is inadequate?
A) Linezolid has no clinically useful activity against Gram-negative organisms because it cannot efficiently penetrate the Gram-negative outer membrane, which acts as a permeability barrier; linezolid monotherapy will leave the Gram-negative component of this mixed infection entirely untreated, and a Gram-negative-active agent must be added
B) Linezolid is contraindicated in post-surgical patients because its MAO inhibitory activity interacts with the adrenergic agents commonly used for hemodynamic support in the ICU, producing hypertensive crises that would worsen the patient's clinical status
C) Linezolid is bacteriostatic and therefore inadequate for any serious infection requiring bactericidal activity; both the Gram-positive and Gram-negative components of this wound infection require bactericidal therapy, and linezolid should not be used in either case
D) Linezolid cannot be used for wound infections because its tissue penetration into surgical wound beds is inadequate; its high volume of distribution causes preferential sequestration in vascular compartments rather than the extravascular tissue spaces where the infection is located
E) Linezolid activity against Gram-positive organisms in this setting is also insufficient because wound infections caused by staphylococci specifically require bactericidal agents; linezolid's bacteriostatic mechanism precludes its use against any staphylococcal wound infection regardless of susceptibility
ANSWER: A
Rationale:
Linezolid's antimicrobial spectrum is restricted exclusively to Gram-positive organisms. It has no clinically useful activity against Gram-negative bacteria because it cannot efficiently penetrate the Gram-negative outer membrane, which acts as a permeability barrier preventing oxazolidinones from reaching intracellular concentrations necessary for ribosomal inhibition. In this mixed wound infection with both Gram-positive cocci (likely staphylococci) and Gram-negative rods, linezolid monotherapy would provide coverage only for the Gram-positive component while leaving Gram-negative pathogens — which could include Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, or Enterobacter species in a post-surgical abdominal setting — completely untreated. This gap in coverage in a surgical ICU patient with a post-abdominal-surgery wound infection represents a potentially life-threatening prescribing error. A Gram-negative-active agent (such as a beta-lactam/beta-lactamase inhibitor combination, a carbapenem, or an antipseudomonal agent depending on local epidemiology) must be added.
Option B: Option B is incorrect because while linezolid does have MAO inhibitory activity that can interact with serotonergic agents, its interaction with adrenergic vasopressors used for hemodynamic support is not the primary reason monotherapy is inadequate here; and the interaction with vasopressors, while possible, is not an absolute contraindication to use; the critical gap is Gram-negative coverage.
Option C: Option C is incorrect because characterizing linezolid as inadequate for any serious infection on the basis of bacteriostatic activity overstates the limitation; linezolid is an appropriate treatment for serious Gram-positive infections including MRSA pneumonia and VRE infections in selected patients; the problem in this specific case is spectrum, not the bacteriostatic property per se.
Option D: Option D is incorrect because linezolid has a volume of distribution of approximately 40 to 50 liters, indicating substantial tissue distribution; it achieves good concentrations in skin, soft tissue, and surgical wound beds; inadequate tissue penetration is not the reason it should not be used as monotherapy in this scenario.
Option E: Option E is incorrect because while linezolid is bacteriostatic against staphylococci and not appropriate for MRSA bacteremia, it is an accepted treatment for staphylococcal skin and soft tissue infections, including those caused by MRSA; the absolute contraindication is for bacteremia and endocarditis, not for all staphylococcal wound infections.
8. A 48-year-old patient with treatment-resistant depression has been stable on sertraline 150 mg daily for 3 years. She develops a vancomycin-resistant Enterococcus faecium (VRE) urinary tract infection that has spread to the bloodstream. The infectious disease team determines that linezolid is the appropriate antibiotic. Which of the following correctly describes the pharmacodynamic interaction risk and the recommended clinical approach?
A) The combination is safe because sertraline acts on presynaptic serotonin transporters while linezolid acts on bacterial ribosomes; these mechanisms are pharmacologically independent and do not interact through any shared pathway relevant to serotonin toxicity
B) Linezolid inhibits CYP2D6, the primary enzyme metabolizing sertraline, causing sertraline to accumulate to toxic levels; the correct management is to reduce the sertraline dose by 50% and monitor for sertraline-specific side effects including QTc prolongation and sedation
C) Serotonin syndrome risk exists but is limited to the first 48 hours of combination therapy; after this window the patient develops pharmacodynamic tolerance to the MAO inhibitory effect of linezolid, and the combination becomes safe for the duration of the antibiotic course
D) Linezolid is a reversible nonselective MAO inhibitor (MAOI) that reduces serotonin metabolism; combined with sertraline, which blocks serotonin reuptake into presynaptic neurons, synaptic serotonin accumulates and can produce serotonin syndrome — characterized by mental status changes, autonomic instability, and neuromuscular abnormalities including clonus and hyperreflexia; sertraline should be discontinued if clinically feasible, and the patient must be monitored closely for signs of serotonin toxicity throughout linezolid therapy
E) The interaction between linezolid and sertraline is exclusively pharmacokinetic; sertraline competitively inhibits linezolid's renal tubular secretion, causing linezolid to accumulate to supratherapeutic concentrations; the clinical risk is linezolid toxicity (myelosuppression and neuropathy) rather than serotonin syndrome
ANSWER: D
Rationale:
Linezolid is a reversible, nonselective monoamine oxidase inhibitor (MAOI). MAO is the primary enzyme responsible for degrading serotonin (as well as dopamine and norepinephrine) in presynaptic neurons and the intestinal wall. By inhibiting MAO, linezolid reduces serotonin catabolism and allows serotonin to accumulate at the synapse. Sertraline is a selective serotonin reuptake inhibitor (SSRI) that blocks the serotonin transporter (SERT), preventing reuptake of serotonin from the synapse into the presynaptic neuron. When both mechanisms operate simultaneously, the synapse is flooded with serotonin from two directions — reduced degradation (linezolid's MAOI effect) and reduced reuptake (sertraline's SSRI effect). The resulting serotonin excess can produce serotonin syndrome, which manifests as the triad of mental status changes (agitation, confusion), autonomic instability (hyperthermia, diaphoresis, tachycardia), and neuromuscular abnormalities (clonus, hyperreflexia, myoclonus, tremor). Serotonin syndrome can be life-threatening. The recommended approach when linezolid is urgently needed is to discontinue sertraline if clinically feasible, observe an appropriate washout interval if possible, and monitor closely throughout therapy.
Option A: Option A is incorrect because the pharmacological independence of the two drugs' primary mechanisms (ribosomal inhibition vs. SERT blockade) does not eliminate the interaction — linezolid has a secondary pharmacodynamic effect (MAO inhibition) that directly opposes sertraline's neuropharmacological consequences, and this off-target MAOI property is the basis of the interaction.
Option B: Option B is incorrect because linezolid does not inhibit CYP2D6 to a clinically meaningful extent; its drug interactions are not mediated by CYP enzyme inhibition; the interaction with sertraline is pharmacodynamic through the shared serotonin pathway, not pharmacokinetic through CYP2D6.
Option C: Option C is incorrect because pharmacodynamic tolerance to MAOI activity does not develop over 48 hours; linezolid's MAO inhibition is present throughout the treatment course, and the risk of serotonin syndrome persists as long as both agents are co-administered.
Option E: Option E is incorrect because linezolid is not primarily eliminated by renal tubular secretion, and sertraline does not inhibit transporters relevant to linezolid clearance; the risk of combination therapy is serotonin syndrome — a pharmacodynamic interaction — not linezolid accumulation from a pharmacokinetic mechanism.
9. A 55-year-old patient receiving linezolid for MRSA osteomyelitis is now in week 4 of therapy. Weekly CBC shows a platelet count falling from 210,000 at baseline to 95,000/mcL at week 4, with concurrent mild anemia. The patient is asymptomatic. Which of the following correctly identifies the mechanism of this finding, its expected course, and the appropriate monitoring standard?
A) This represents linezolid-induced immune thrombocytopenic purpura (ITP), in which linezolid acts as a hapten that binds platelet surface glycoproteins and generates antiplatelet antibodies; the process is irreversible unless immunosuppressive therapy is initiated, and platelet transfusion is the immediate management
B) This is dose- and duration-dependent myelosuppression from inhibition of mitochondrial protein synthesis in bone marrow precursor cells — the same mechanism as linezolid's antibacterial activity; thrombocytopenia is the most consistently observed hematologic effect, concurrent with anemia and potential leukopenia; the toxicity is fully reversible upon drug discontinuation, and weekly CBC monitoring is the standard of care for courses exceeding 2 weeks
C) The falling platelet count reflects linezolid's selective inhibition of thrombopoietin (TPO) receptor signaling in megakaryocytes, which reduces platelet production specifically while sparing erythroid and myeloid lineages; this mechanism is distinct from the reversible bone marrow suppression seen with chloramphenicol and does not reverse with drug discontinuation
D) This is an expected and acceptable finding during linezolid therapy that requires no action; platelet counts in the range of 80,000 to 100,000/mcL represent the pharmacodynamically active range that correlates with optimal linezolid antibacterial effect, and values in this range predict therapeutic success
E) The combined thrombocytopenia and anemia indicate that linezolid has produced aplastic anemia through the same idiosyncratic stem cell destruction mechanism as chloramphenicol; the prognosis is identical to chloramphenicol aplastic anemia, with greater than 50% mortality without bone marrow transplantation
ANSWER: B
Rationale:
This presentation is consistent with linezolid's well-characterized, dose- and duration-dependent myelosuppression. Linezolid inhibits mitochondrial protein synthesis in bone marrow precursor cells, exploiting the structural similarity between mitochondrial ribosomes and bacterial 70S ribosomes. This is the same molecular mechanism responsible for its antibacterial activity. Thrombocytopenia is the most consistently observed hematologic toxicity and typically appears after 10 to 14 days of therapy, with risk increasing with treatment duration — as in this patient at 4 weeks. Anemia and leukopenia can also occur. All hematologic toxicity is reversible upon drug discontinuation, as the mechanism is pharmacological inhibition of mitochondrial function in rapidly dividing marrow cells rather than destruction of stem cells. Weekly CBC monitoring is the standard of care for courses exceeding 2 weeks. Risk factors for more severe toxicity include renal impairment (which reduces clearance of linezolid metabolites), baseline thrombocytopenia, and prolonged courses. The clinical decision at week 4 with a platelet count of 95,000/mcL is to reassess the need for continued linezolid, consider whether an alternative MRSA agent can be substituted, and continue close monitoring.
Option A: Option A is incorrect because linezolid-associated thrombocytopenia is not an immune-mediated hapten reaction; it is a direct mitochondrial toxicity affecting marrow precursors; the process is not irreversible and does not require immunosuppression; the described mechanism is that of heparin-induced thrombocytopenia or certain drug-induced ITP reactions, not linezolid toxicity.
Option C: Option C is incorrect because linezolid does not selectively inhibit thrombopoietin receptor signaling; its myelosuppressive effect involves all hematopoietic cell lines through mitochondrial protein synthesis inhibition, not a thrombopoietin-specific pathway; the toxicity is reversible with drug discontinuation.
Option D: Option D is incorrect because a falling platelet count in this clinical context is not a pharmacodynamic target or marker of antibacterial efficacy; it is an adverse effect requiring clinical attention, and the premise that thrombocytopenia predicts therapeutic success is pharmacologically unsupported and clinically dangerous.
Option E: Option E is incorrect because linezolid myelosuppression is mechanistically distinct from chloramphenicol aplastic anemia; linezolid causes reversible mitochondrial toxicity in marrow precursors (not stem cell destruction), the thrombocytopenia and anemia described are characteristic of reversible suppression, and the prognosis with drug discontinuation is excellent recovery rather than the greater than 50% mortality associated with chloramphenicol aplastic anemia.
10. A 67-year-old patient with a permanent pacemaker presents with fever, bacteremia, and two blood cultures growing MRSA. A medical student on the team notes that linezolid showed superiority to vancomycin for MRSA pneumonia in a major clinical trial and suggests starting linezolid for this bloodstream infection. The attending physician declines and selects vancomycin instead. Which of the following best justifies the attending's decision?
A) Linezolid is not approved by the FDA for bloodstream infections caused by any pathogen and cannot be used for bacteremia regardless of organism or clinical circumstance; vancomycin is the only agent with regulatory approval for MRSA bacteremia
B) Linezolid's superiority in MRSA pneumonia reflects its lung-specific pharmacokinetic properties; it achieves poor blood concentrations relative to tissue concentrations and therefore cannot achieve the minimum inhibitory concentration against MRSA in the bloodstream even at standard doses
C) Linezolid's MAO inhibitory activity would interact with the anesthetic agents required for pacemaker pocket revision surgery, making it pharmacologically unsafe in a patient who may require an operative procedure
D) Linezolid produces myelosuppression that would compromise the patient's immune response during bacteremia, and the risk of neutropenia during an active bloodstream infection outweighs any antibacterial benefit
E) Linezolid is bacteriostatic against Staphylococcus aureus including MRSA; serious bloodstream infections, particularly bacteremia with a permanent device in place, require bactericidal therapy to reliably clear the bloodstream and prevent seeding of the pacemaker hardware; clinical trial evidence shows inferior outcomes with linezolid compared to vancomycin or daptomycin for MRSA bloodstream infections
ANSWER: E
Rationale:
Linezolid is bacteriostatic against Staphylococcus aureus — including MRSA — meaning it inhibits bacterial growth without reliably killing organisms. Bloodstream infections, particularly in the setting of an intravascular device such as a permanent pacemaker, require bactericidal therapy to clear bacteria from the circulation and prevent device seeding, endovascular infection, and embolic complications such as septic emboli to the lungs or other organs. Clinical trial data for MRSA bacteremia demonstrate inferior outcomes with linezolid compared to bactericidal agents (vancomycin or daptomycin). This stands in contrast to MRSA pneumonia, where linezolid demonstrated superiority to vancomycin (ZEPHYR trial) due to its pharmacokinetic advantages in the pulmonary compartment. The critical insight is that linezolid's performance in one anatomical compartment (the lung) cannot be extrapolated to another (the bloodstream). Using linezolid for MRSA bacteremia based on its pneumonia trial results is a recognized prescribing error that can result in treatment failure and patient harm.
Option A: Option A is incorrect because the limitation on linezolid in MRSA bacteremia is not a regulatory prohibition; linezolid has FDA approval for various Gram-positive infections, and its avoidance in bacteremia is based on clinical evidence and mechanism, not a labeling ban; the characterization of vancomycin as the "only approved" agent for MRSA bacteremia is also incorrect given daptomycin's approval.
Option B: Option B is incorrect because linezolid has a volume of distribution of approximately 40 to 50 liters and distributes well throughout the body including vascular compartments; it achieves plasma concentrations adequate to inhibit MRSA growth; the problem is bacteriostatic activity producing insufficient bacterial killing, not inadequate blood-compartment drug exposure.
Option C: Option C is incorrect because while linezolid has MAOI activity and drug interactions with certain serotonergic agents, interactions with standard anesthetic agents are not the primary reason to avoid linezolid in this scenario; the pharmacological basis for the attending's decision is the bacteriostatic-versus-bactericidal distinction.
Option D: Option D is incorrect because while linezolid does cause myelosuppression with prolonged courses, this is not the primary reason to avoid it for acute MRSA bacteremia; the reasoning based on neutropenia risk during bacteremia does not reflect the established clinical guideline rationale, which is bacteriostatic activity and inferior clinical trial outcomes.
11. A pulmonary/critical care fellow is reviewing the clinical evidence for linezolid versus vancomycin in MRSA infections. She asks a resident to identify for which specific infection type linezolid has demonstrated clinical superiority to vancomycin, and to explain the pharmacological basis for that advantage. Which of the following correctly identifies the infection type and the proposed mechanism?
A) Linezolid demonstrated superiority to vancomycin for MRSA bacteremia originating from intravascular catheters; the proposed mechanism is that linezolid's small molecular size allows it to penetrate biofilm on catheter surfaces more efficiently than vancomycin's large glycopeptide structure
B) Linezolid demonstrated superiority to vancomycin for MRSA endocarditis; the proposed mechanism is linezolid's direct inhibition of staphylococcal toxin production at sub-inhibitory concentrations, which reduces vegetation formation independently of bacterial killing
C) Linezolid demonstrated clinical superiority to vancomycin for MRSA nosocomial pneumonia including ventilator-associated pneumonia; the proposed mechanisms include linezolid's superior penetration into pulmonary epithelial lining fluid — achieving concentrations several times higher than simultaneous plasma levels — and more predictable pharmacokinetics compared to vancomycin's renal function-dependent and variable dosing requirements
D) Linezolid demonstrated superiority to vancomycin for MRSA skin and soft tissue infections in outpatient settings; the proposed mechanism is linezolid's approximately 100% oral bioavailability allowing home-based therapy that maintains higher time-above-MIC than vancomycin's intermittently dosed IV regimen
E) Linezolid demonstrated superiority to vancomycin for all serious MRSA infections uniformly across infection sites including pneumonia, bacteremia, and skin infections; the pharmacological basis is linezolid's inhibition of staphylococcal ribosomal RNA transcription, which vancomycin's cell wall mechanism cannot replicate
ANSWER: C
Rationale:
The ZEPHYR trial (Wunderink et al., Clinical Infectious Diseases, 2012) was a randomized controlled trial demonstrating linezolid's clinical superiority to vancomycin specifically for MRSA nosocomial pneumonia, including ventilator-associated pneumonia. The proposed mechanisms for this advantage are pharmacokinetically based: linezolid achieves pulmonary epithelial lining fluid (ELF) concentrations that are several times higher than simultaneous plasma concentrations, providing greater drug exposure at the site of infection in the lung than plasma levels would suggest. Vancomycin, by contrast, achieves more limited and variable lung penetration. Additionally, linezolid's fixed dosing (600 mg every 12 hours, adjusted only for oral-to-IV transition) produces more predictable pharmacokinetics than vancomycin, whose dosing requires adjustment for renal function, weight, and measured trough levels. Critically, this superiority is specific to MRSA pneumonia and does not extend to MRSA bacteremia or endocarditis, where linezolid's bacteriostatic activity against staphylococci produces inferior outcomes.
Option A: Option A is incorrect because linezolid's clinical trial evidence of superiority to vancomycin is in MRSA pneumonia, not catheter-related bacteremia; linezolid is specifically not recommended for MRSA bacteremia due to bacteriostatic activity and inferior outcomes; the biofilm penetration rationale described is not the established evidence base.
Option B: Option B is incorrect because linezolid is not recommended for MRSA endocarditis; endocarditis requires bactericidal therapy, and there is no major randomized trial showing linezolid superiority for endocarditis; the virulence factor inhibition mechanism, while pharmacologically described, is not the basis of the clinical evidence for pneumonia superiority.
Option D: Option D is incorrect because the clinical superiority demonstration for linezolid versus vancomycin is in nosocomial pneumonia (an inpatient setting), not in outpatient skin and soft tissue infections; while linezolid's oral bioavailability is a clinical advantage, it is not the basis of the comparative trial evidence of superiority.
Option E: Option E is incorrect because linezolid's demonstrated superiority to vancomycin is specifically limited to MRSA pneumonia; it is not superior across all serious MRSA infections; characterizing it as uniformly superior across bacteremia and skin infections contradicts the clinical trial evidence and the established prescribing guidance against using linezolid for MRSA bacteremia.
12. A patient with acute bacterial skin and skin structure infection (ABSSSI) caused by MRSA is being evaluated for outpatient oral antibiotic therapy. The clinician is choosing between linezolid and tedizolid. Which of the following most accurately describes the pharmacokinetic feature of tedizolid that makes it pharmacologically distinct from linezolid in a way that directly supports the shorter approved treatment duration?
A) Tedizolid is administered as the prodrug tedizolid phosphate, rapidly converted to the active moiety by plasma phosphatases after absorption; it has a half-life of approximately 12 hours supporting once-daily dosing and is approximately 4 to 8 times more potent than linezolid against staphylococci and enterococci by MIC, allowing a 6-day course at 200 mg once daily to achieve equivalent antibacterial effect to linezolid's 10 to 14-day course at 600 mg twice daily
B) Tedizolid is a direct-acting compound that does not require prodrug conversion; it has a shorter half-life than linezolid (approximately 2 hours) that necessitates three-times-daily dosing but produces higher peak tissue concentrations that sterilize infected skin tissue more rapidly, supporting a shorter treatment duration
C) Tedizolid is metabolized by CYP3A4 to a more potent active hydroxylated metabolite in the liver; this hepatic bioactivation produces an active metabolite with a half-life of 24 hours that accumulates in skin tissue during once-daily dosing, providing the prolonged drug exposure needed to justify the 6-day approval
D) Tedizolid achieves oral bioavailability of only 60% compared to linezolid's 100%, but its higher degree of protein binding (greater than 95%) creates a plasma reservoir that sustains tissue concentrations between doses, reducing the required dosing frequency despite the lower absorbed fraction
E) Tedizolid has the same half-life as linezolid and requires twice-daily dosing; the 6-day approval reflects a regulatory decision based on non-inferiority trial results rather than any pharmacokinetic or pharmacodynamic advantage that would mechanistically explain a shorter treatment duration
ANSWER: A
Rationale:
Tedizolid phosphate is a prodrug that is rapidly and efficiently converted to the active tedizolid moiety by plasma and tissue phosphatases after oral or IV administration. It has an oral bioavailability exceeding 90% and a half-life of approximately 12 hours — roughly twice that of linezolid (4.5 to 5.5 hours) — which pharmacokinetically supports once-daily dosing. The longer half-life means drug concentrations remain above the MIC for susceptible staphylococci and enterococci for a greater proportion of the dosing interval. Additionally, tedizolid is approximately 4 to 8 times more potent than linezolid by MIC against these organisms, meaning that lower total daily drug exposure is required to achieve equivalent or superior antibacterial effect. Together, the higher intrinsic potency and more favorable pharmacokinetics allow the approved regimen of 200 mg once daily for 6 days to be therapeutically equivalent to linezolid's 600 mg twice daily for 10 to 14 days for ABSSSI, as demonstrated in the ESTABLISH-1 and ESTABLISH-2 trials.
Option B: Option B is incorrect because tedizolid does require prodrug conversion; it is administered as the phosphate ester, not as the active form; and its half-life of approximately 12 hours supports once-daily dosing — the opposite of the three-times-daily regimen described.
Option C: Option C is incorrect because tedizolid is not metabolized by CYP3A4 to a more potent active metabolite; like linezolid, it does not rely on CYP enzymes for activation or metabolism; its pharmacokinetic advantage over linezolid comes from its own pharmacological properties after phosphatase-mediated prodrug conversion, not from hepatic bioactivation.
Option D: Option D is incorrect because tedizolid's oral bioavailability exceeds 90%, not 60%; the high bioavailability is a pharmacokinetic advantage, not a limitation partially offset by protein binding; and while tedizolid does have higher protein binding than linezolid, this is not the pharmacokinetic basis for the once-daily dosing schedule.
Option E: Option E is incorrect because tedizolid's half-life of approximately 12 hours is approximately twice that of linezolid and is a genuine pharmacokinetic basis for once-daily dosing; characterizing the shorter treatment duration as solely a regulatory decision without mechanistic basis misrepresents the pharmacology underlying the clinical trial design and approval rationale.
13. An infectious disease consultant is asked to manage bacterial meningitis in a patient with a documented history of anaphylaxis to both penicillin and cephalosporins. The team asks why chloramphenicol remains a viable option for meningitis when so many other antibiotics cannot be used in this scenario. Which of the following correctly explains the pharmacokinetic property of chloramphenicol that supports its use in this indication?
A) Chloramphenicol is actively transported across the choroid plexus by a dedicated ATP-binding cassette (ABC) transporter that concentrates the drug in the CSF to levels 3 to 5 times higher than simultaneous plasma concentrations; this active transport is constitutively expressed regardless of meningeal inflammation
B) Chloramphenicol binds avidly to CSF proteins at physiologic pH, creating a CSF drug depot that provides sustained antibacterial activity for 12 to 24 hours after each dose despite rapid systemic clearance; this depot effect maintains therapeutic CSF concentrations between doses without requiring continuous high plasma levels
C) Chloramphenicol penetrates the blood-brain barrier only when meningeal inflammation increases permeability; the inflamed meninges allow passive diffusion of large polar molecules including chloramphenicol, which would otherwise be excluded from the CSF by intact tight junctions
D) Chloramphenicol is a lipophilic, largely un-ionized molecule at physiologic pH that crosses lipid bilayers by passive diffusion; it achieves CSF concentrations of approximately 30 to 50% of simultaneous plasma concentrations even in the absence of meningeal inflammation, with CSF levels approaching plasma levels when meninges are inflamed — a degree of CNS penetration superior to most beta-lactam antibiotics and sufficient to achieve bactericidal concentrations against the common meningeal pathogens
E) Chloramphenicol penetrates the blood-brain barrier by piggybacking on the large neutral amino acid transporter (LAT1), which normally imports phenylalanine and leucine into CNS tissue; the drug's aromatic ring structure is recognized by LAT1 as a substrate analog, enabling saturable but high-capacity CNS uptake
ANSWER: D
Rationale:
Chloramphenicol's CNS penetration is its most clinically distinctive pharmacokinetic property and the primary pharmacological basis for its continued use in bacterial meningitis when beta-lactams cannot be administered. Chloramphenicol is lipophilic and largely un-ionized at physiologic pH, physicochemical properties that allow it to cross lipid bilayers — including the blood-brain barrier — by passive diffusion without requiring active transport. It achieves CSF concentrations of approximately 30 to 50% of simultaneous plasma concentrations even in the absence of meningeal inflammation, and CSF levels approach plasma levels when the meninges are inflamed and barrier permeability is increased. This passive diffusion-based penetration is superior to that of most beta-lactam antibiotics (which are more polar and more ionized at physiologic pH, relying heavily on inflammation-enhanced permeability). Combined with its bactericidal activity against the common meningeal pathogens — Haemophilus influenzae, Neisseria meningitidis, and Streptococcus pneumoniae — this CNS penetration makes chloramphenicol pharmacologically suitable for bacterial meningitis in beta-lactam-allergic patients.
Option A: Option A is incorrect because chloramphenicol crosses the blood-brain barrier by passive diffusion based on its lipophilic physicochemical properties, not by active ABC transporter-mediated uptake; there is no dedicated ABC transporter that concentrates chloramphenicol in CSF; active transport concentrating mechanisms are not the established explanation for its penetration.
Option B: Option B is incorrect because chloramphenicol does not bind avidly to CSF proteins to form a depot; it distributes freely based on its physicochemical properties, and the sustained penetration results from its passive diffusion capability rather than a protein-binding reservoir effect.
Option C: Option C is incorrect because chloramphenicol does not require inflamed meninges for adequate CSF penetration — this is in fact one of its key advantages; penetration of approximately 30 to 50% of plasma even without inflammation distinguishes it from drugs that rely primarily on inflammation-enhanced permeability for therapeutic CSF levels.
Option E: Option E is incorrect because chloramphenicol does not use the LAT1 amino acid transporter for CNS entry; passive diffusion through lipid bilayers is the established mechanism; LAT1-mediated transport is relevant for certain amino acid analogs used in positron emission tomography (PET) imaging and for some investigational CNS drugs, but not for chloramphenicol.
14. A clinical microbiologist presents a linezolid-resistant MRSA isolate to the infectious disease team. She explains that two distinct resistance mechanisms account for most clinical oxazolidinone resistance in staphylococci and enterococci, and that one of them also confers cross-resistance to chloramphenicol. Which of the following correctly describes both mechanisms and explains why one confers cross-resistance to chloramphenicol?
A) Efflux pump upregulation via the MFS (major facilitator superfamily) reduces intracellular linezolid concentrations; chloramphenicol cross-resistance occurs because the same efflux pump recognizes and exports both drugs; high-level resistance requires only a single efflux gene acquisition, unlike the multi-copy mutation mechanism needed for ribosomal target alteration
B) Point mutations in the 23S rRNA gene — particularly at positions 2447, 2504, and 2576 — reduce linezolid binding to the 50S subunit; separately, acquisition of the cfr gene encodes an rRNA methyltransferase that methylates adenine at position A2503 in the 23S rRNA, which reduces binding affinity for both oxazolidinones and chloramphenicol because the binding sites of both drug classes overlap at or near this methylated residue
C) Enzymatic inactivation by a linezolid-specific acetyltransferase modifies the oxazolidinone ring and is the dominant resistance mechanism; cross-resistance to chloramphenicol does not occur because chloramphenicol's nitrobenzene structure is not a substrate for the acetyltransferase; the two drugs are inactivated by entirely independent enzymatic systems
D) Mutations in ribosomal protein L3 sterically displace the oxazolidinone binding pocket and simultaneously expose the peptidyl transferase center to chloramphenicol binding, paradoxically creating chloramphenicol hypersensitivity rather than cross-resistance in L3-mutant strains
E) Plasmid-mediated acquisition of the vanA gene cluster confers cross-class resistance to oxazolidinones and chloramphenicol by modifying the 23S rRNA binding site through an enzymatic pathway analogous to its role in vancomycin resistance; vanA-positive organisms are therefore predictably resistant to all three antibiotic classes simultaneously
ANSWER: B
Rationale:
Two mechanisms account for most clinical oxazolidinone resistance in staphylococci and enterococci. First, point mutations in the 23S rRNA gene — particularly at positions 2447, 2504, and 2576 — reduce the affinity of linezolid (and tedizolid) for their binding site on the 50S subunit. Because bacteria carry multiple copies of the 23S rRNA gene (staphylococci carry 5 to 6 copies), high-level resistance requires accumulation of mutations in multiple gene copies simultaneously; single-copy mutations produce only low-level resistance and are more easily selected during prolonged therapy. Second, the cfr (chloramphenicol-florfenicol resistance) gene encodes an rRNA methyltransferase that methylates the adenine residue at position A2503 in the 23S rRNA. This methylation reduces drug binding at a region critical for both oxazolidinones and chloramphenicol, because both drug classes bind at overlapping or adjacent sites in the peptidyl transferase region of the 50S subunit near A2503. The result is transferable, plasmid-mediated cross-resistance to both chloramphenicol and oxazolidinones. The cfr gene originated in livestock staphylococci and has spread to human clinical isolates. Tedizolid retains activity against isolates with single 23S rRNA point mutations but not against cfr-positive isolates.
Option A: Option A is incorrect because efflux pump upregulation is not the dominant clinical resistance mechanism for oxazolidinones in staphylococci; it is a minor contributor compared to ribosomal target modification; and characterizing efflux as conferring chloramphenicol cross-resistance through pump co-recognition overstates the evidence for this mechanism in clinical resistance.
Option C: Option C is incorrect because enzymatic acetyltransferase inactivation of the oxazolidinone ring is not a clinically established resistance mechanism for linezolid; acetyltransferases are major resistance mechanisms for aminoglycosides and chloramphenicol, but not for oxazolidinones; describing this as the dominant mechanism misrepresents the field.
Option D: Option D is incorrect because L3 protein mutations have been described in some resistant isolates but are not the dominant clinical mechanism; the consequence of L3 mutations is reduced linezolid binding, not chloramphenicol hypersensitivity; paradoxical hypersensitivity through structural rearrangement is not a described phenomenon.
Option E: Option E is incorrect because vanA encodes D-Ala-D-Lac ligases that modify peptidoglycan precursors conferring vancomycin resistance; it has no effect on the ribosome and no role in oxazolidinone or chloramphenicol resistance; the three resistance mechanisms (vancomycin, oxazolidinone, chloramphenicol) are pharmacologically unrelated at the target level.
15. A 29-year-old patient with extensively drug-resistant tuberculosis (XDR-TB) has been receiving linezolid as part of a salvage regimen for 5 months. She reports progressive numbness and tingling in both feet and hands over the past 6 weeks, and her visual acuity has decreased with new difficulty distinguishing red from green. Neurological examination confirms distal sensory loss and central color vision defect. Which of the following correctly identifies the mechanism, reversibility, and recommended preventive strategy for prolonged linezolid use?
A) The findings represent linezolid-induced folate deficiency neuropathy caused by inhibition of dihydrofolate reductase in Schwann cells and retinal ganglion cells; folinic acid (leucovorin) supplementation prevents and reverses both peripheral and optic manifestations; the neuropathy is completely reversible within 4 to 8 weeks of starting supplementation even without drug discontinuation
B) The findings are caused by linezolid-induced vitamin B12 deficiency from inhibition of methionine synthase in neural tissue; cyanocobalamin injections are required and will fully reverse both neuropathies within 3 to 6 months; drug discontinuation is unnecessary if B12 supplementation is adequate
C) The neuropathy reflects immune-mediated vasculitis of the vasa nervorum triggered by linezolid's oxidative metabolites; high-dose corticosteroids are required to prevent progression; drug continuation is possible if steroids are initiated within the first 2 weeks of symptom onset
D) The peripheral and optic neuropathy are caused by linezolid accumulation in dorsal root ganglion cells and retinal ganglion cells due to their high lipid content; dose reduction to 300 mg every 12 hours prevents further accumulation while maintaining adequate anti-TB activity; the neuropathy at this stage is irreversible because the drug is covalently bound to neuronal proteins
E) Prolonged linezolid therapy — particularly courses exceeding 28 days as used in XDR-TB — causes peripheral neuropathy and optic neuropathy through mitochondrial dysfunction in neurons; both may be irreversible if linezolid is not discontinued promptly; monthly ophthalmologic and neurological assessment is standard for courses exceeding 4 weeks; pyridoxine (vitamin B6) supplementation is used in these patients and may partially mitigate neurotoxicity through an incompletely understood mechanism
ANSWER: E
Rationale:
Prolonged linezolid therapy is associated with two forms of neurological toxicity: peripheral neuropathy (distal paresthesias and sensory loss in a stocking-glove distribution) and optic neuropathy (progressive visual loss, color vision disturbance, central scotoma). Both result from linezolid's inhibition of mitochondrial protein synthesis in neurons — the same mechanism responsible for its myelosuppressive and antibacterial effects, exploiting the similarity between mitochondrial and bacterial 70S ribosomes. Neurons have exceptionally high mitochondrial energy demands, making them particularly vulnerable to mitochondrial dysfunction with sustained drug exposure. Unlike the reversible myelosuppression seen with shorter courses, peripheral and optic neuropathy from prolonged linezolid therapy may be irreversible, particularly optic neuropathy — patients who do not discontinue linezolid promptly after symptom onset risk permanent visual impairment. Monthly ophthalmologic and neurological monitoring is therefore standard for courses exceeding 4 weeks. Pyridoxine (vitamin B6) supplementation is used in patients receiving linezolid for XDR-TB, where multi-month courses are unavoidable, and may partially reduce neurotoxicity risk through a mechanism that is not fully characterized but may relate to mitochondrial coenzyme function.
Option A: Option A is incorrect because linezolid neuropathy is not caused by dihydrofolate reductase inhibition; folinic acid is not the treatment; and the framing that full reversal occurs within weeks without drug discontinuation is clinically inaccurate — prompt drug discontinuation is essential when neuropathy is detected.
Option B: Option B is incorrect because linezolid neuropathy is not caused by B12 deficiency or methionine synthase inhibition; cyanocobalamin supplementation does not treat or reverse linezolid mitochondrial neuropathy; and drug discontinuation is frequently necessary to halt progression.
Option C: Option C is incorrect because linezolid neuropathy is not an immune vasculitic process; corticosteroids are not part of management; the mitochondrial mechanism applies whether or not there is an inflammatory component, and the window for steroid intervention described does not reflect established management practice.
Option D: Option D is incorrect because the neuropathy is not from lipid-sequestration-based drug accumulation in ganglion cells; dose reduction to 300 mg every 12 hours is not a validated strategy for preventing neuropathy while maintaining anti-TB efficacy; and covalent protein binding is not the mechanism of linezolid's neurotoxicity.
16. An infectious disease specialist is comparing tedizolid and linezolid for a patient who requires prolonged oxazolidinone therapy. She reviews tedizolid's clinical advantages and its activity against linezolid-resistant organisms. Which of the following most accurately summarizes tedizolid's pharmacological profile relative to linezolid, including its limitations against resistant strains?
A) Tedizolid is equivalent in potency to linezolid but produces less myelosuppression because it lacks the MAOI activity responsible for linezolid's mitochondrial toxicity in bone marrow; it retains full activity against all linezolid-resistant organisms including those carrying the cfr gene because its prodrug activation pathway generates a structurally distinct active compound that binds to a non-overlapping 50S site
B) Tedizolid is more potent than linezolid and produces less myelosuppression; it retains activity against cfr-positive isolates because the phosphatase-mediated prodrug activation irreversibly displaces the A2503 methylation added by the cfr methyltransferase, restoring oxazolidinone binding affinity at the target site
C) Tedizolid is approximately 4 to 8 times more potent than linezolid against staphylococci and enterococci by MIC and produces significantly less myelosuppression in clinical trials; it retains activity against some isolates with single 23S rRNA point mutations that confer linezolid resistance, but does NOT retain activity against cfr-positive isolates because the cfr-mediated methylation at A2503 reduces binding affinity for all oxazolidinones
D) Tedizolid offers no potency advantage over linezolid against wild-type organisms; its primary advantage is pharmacokinetic — the 12-hour half-life reduces the total number of doses administered during a treatment course, which reduces cumulative mitochondrial exposure and produces less myelosuppression without altering the antibacterial effect
E) Tedizolid retains activity against all linezolid-resistant strains regardless of resistance mechanism because its once-daily pharmacokinetics achieve higher peak concentrations that overcome resistance through concentration-dependent killing; cfr-positive isolates are susceptible to tedizolid at standard doses because peak-to-MIC ratio, not time-above-MIC, governs oxazolidinone activity
ANSWER: C
Rationale:
Tedizolid has several pharmacological advantages over linezolid, but its activity against resistant organisms has specific and important limitations. Tedizolid is approximately 4 to 8 times more potent than linezolid against staphylococci and enterococci by MIC, which allows the lower 200 mg once-daily dose to achieve equivalent antibacterial effect to linezolid's 600 mg twice-daily regimen. It produces significantly less myelosuppression than linezolid in clinical trials, attributed to its lower daily dose and more favorable pharmacokinetics reducing total cumulative mitochondrial exposure. Regarding resistant organisms: tedizolid retains activity against some isolates with single point mutations in the 23S rRNA gene (e.g., position 2576) that confer linezolid resistance, because tedizolid's higher intrinsic potency and slightly different binding geometry allow it to bind despite a single mutated rRNA copy. However, tedizolid does NOT retain activity against cfr-positive isolates — because cfr-mediated methylation at position A2503 of the 23S rRNA reduces binding affinity for all drugs in the oxazolidinone class, including tedizolid, by modifying the shared binding region on the 50S subunit. This is a critical clinical distinction when considering tedizolid as a treatment for linezolid-resistant infections.
Option A: Option A is incorrect because tedizolid does not retain activity against cfr-positive isolates; the prodrug activation pathway does not displace A2503 methylation; and characterizing tedizolid's advantage as absence of MAOI activity conflates two distinct mechanisms — both linezolid and tedizolid have MAOI activity, and myelosuppression is caused by mitochondrial protein synthesis inhibition, not by MAO inhibition.
Option B: Option B is incorrect because prodrug conversion by phosphatases is a systemic pharmacokinetic event and does not interact with or reverse ribosomal RNA methylation at the target site; the cfr methylation is a bacterial ribosomal modification that affects drug-ribosome binding, not a modification that can be displaced by the drug's activation chemistry.
Option D: Option D is incorrect because tedizolid does have a genuine potency advantage over linezolid — it is approximately 4 to 8 times more potent by MIC; characterizing the advantages as purely pharmacokinetic understates the pharmacodynamic basis for the lower dose requirement and shorter approved treatment duration.
Option E: Option E is incorrect because oxazolidinones are time-dependent antibiotics, not concentration-dependent; their activity is governed by the proportion of the dosing interval that drug concentrations remain above the MIC (time-above-MIC), not by peak-to-MIC ratio; and tedizolid does not overcome cfr resistance through concentration-dependent mechanisms at standard clinical doses.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.